Prosecution Insights
Last updated: November 04, 2026
Application No. 17/439,732

MODIFIED GLUCAGON MOLECUES AND FORMULATIONS WITH OXIDATION RESISTANCE AND METHODS AND KITS OF EMPLOYING THE SAME

Final Rejection §103
Filed
Sep 15, 2021
Priority
Mar 15, 2019 — provisional 62/818,826 +1 more
Examiner
KATAKAM, SUDHAKAR
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Monon Bioventures LLC
OA Round
4 (Final)
75%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
977 granted / 1307 resolved
+14.8% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
83 currently pending
Career history
1385
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
44.6%
+4.6% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1307 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the application Receipt of applicant’s remarks and claim amendments filed on 08/10/2026 are acknowledged. In light of claim amendments, the previous 102 rejections are withdrawn. However, applicants’ arguments for the previous 103 rejections are found not persuasive. Accordingly, the previous rejection is maintained and modified to address claim amendments. Response to Arguments (1) Applicants argue that The Office's proposed combination assumes, without support, that effects of the two modifications are predictable and additive. Topp teaches a modified glucagon, which is identical to applicants claimed SEQ ID NO:1, wherein a glucagon molecule includes one or more modified amino acids, which results in the glucagon molecule being soluble at a substantially neutral pH, wherein glucagon is phosphorylated at Thr5 or Ser8. Topp further teaches that addition of a phosphate group on these residues can insert a charged and highly hydrophilic groups, and the charged phosphate groups are expected to increase the solubility of the peptide. In addition, Topp recognized the fact that Met27 can be oxidized and so, Topp suggested oxidation of Met27 can be controlled with the addition of EDTA and other formulation approaches known in the art, and further suggested that addition of antioxidants may prevent phosphoglucagon oxidation and improve the long-term storage stability of these peptides in solution [see 0021 and 0080]. To avoid addition of antioxidants to control oxidation of Met27, a skilled person in the art would prefer chemical medication of Met27, such as teachings of Dimarchi, since external addition of antioxidants may have unwanted side effects. Moreover, Dimarchi showed that replacement of Met27 with Leu or Nle resulted in prevention of oxidation and improved solubility and stability. So, combination of both, i.e., phosphorylation and replacement of Met27 with Leu/Nle expected to increase solubility and also stability of the peptide, absence evidence to the contrary. (ii) Applicants argue that applicants’ experimental evidence confirms that the combined properties were not predictable. In Table 1, peptides P1, P2 and P3 have Met27, whereas peptides P5, P6 and P7 have Nle27. These are phosphorylated at Thr5 (P1 and P5), Thr7 (P2 and P6) and Ser8 (P3 and P7). Comparative data reveals that solubility and stability are sensitive to buffer conditions. It appears that not much difference is noticed with the recited buffers, other than in water. Solubility is low for peptides with Nle27, which is expected since Nle27 is hydrophobic in nature. It is not clear what applicants are intend to conclude from the provided data in the table 1, If applicants intend to conclude that all phosphorylated sites are not equal, but which is expected and is known in the art. For example, as applicants pointed out, Topp states "[t]hat phosphor-Ser2- glucagon is not soluble indicates that the site of phosphorylation matters, and that not all phosphate ester derivatives of glucagon will show improved stability" and "not all the phosphorylated derivatives have the same in vivo performance," Topp at paragraphs [0063] and[0086]. (iii) Applicants argue that neither references teaches behavior of the claimed combined modifications. Applicants show how each cited reference differ from the instant invention, but the obviousness test under 35 U.S.C. 103 is whether the invention would have been obvious in view of the prior art taken as a whole. In re Metcalf et al. 157 U.S.P.Q. 423. Applicant is reminded that one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In the instant case, all the art rejections are under 35 USC 103, which relies on the combination of the references together. (iv) Applicants argue that Topp's short-term data does not establish the claimed 3-month oxidation. As explained in the rejection, Topp in combination with Dimarchi cures this deficiency. Dimarchi teaches that the Met residue present at position 27 of the native peptide is changed to Leu or Nle (norleucine) to prevent oxidative degradation of the peptide, and these modified sequences have improved solubility and stability. The preventive oxidative degradation of the peptide is interpreted as or reads applicants ‘peptide exhibits less than 10% oxidation after 3 months when the pharmaceutical composition is stored at 30oC. (v) Applicants argue that Applicants’ results refute the Office’s predictable-results rationale. Fig.6A and 6B describes mass spectrometry results of the samples of Figures 5A-5I, which support that either no or minimal oxidation or degradation occurred in the methionine substituted and antioxidant test samples by week 12. If there is no methionine, there won’t be any oxidation or degradation. This is expected and also evidenced from the teachings of Dimarchi. (vi) Applicants argue that the references provide, at most, a reason to experiment - not a reasonable expectation of the claimed result. A combination of prior art references is only proper if a person of ordinary skill in the art (POSA) at the time of the invention, faced with the same problem, would have been motivated to combine their teachings with a reasonable expectation of success. See KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007). Here, the technical fields and problems addressed by the references are not distinct from that of the present claimed invention. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. (i) Claims 6-14 are rejected under 35 U.S.C. 103 as being unpatentable over Dimarchi (US 2012/0196804 A1) in view of Topp (US 2018/0298076 A1). For claim 6: Dimarchi teaches the following sequence: PNG media_image1.png 81 495 media_image1.png Greyscale [see SEQ ID NO:1]. The above sequence is identical to applicants SEQ ID NO:1. Dimarchi further teaches that the Met residue present at position 27 of the native peptide is changed to Leu or Nle (norleucine) to prevent oxidative degradation of the peptide, and these modified sequences having improved solubility and stability, these are represented by the following disclosed sequences in the teachings of Dimarchi: PNG media_image2.png 198 402 media_image2.png Greyscale [see abstract and page 4]. The above reads applicants claimed modified SEQ ID NO:1. The preventive oxidative degradation of the peptide is interpreted as or reads applicants ‘peptide exhibits less than 10% oxidation after 3 months when the pharmaceutical composition is stored at 30oC”. Dimarchi further discloses that in accordance with one of their embodiments a pharmaceutical composition is provided comprising the novel glucagon peptides disclosed herein, and the pharmaceutical compositions comprise solutions that are sterilized and contained within various packages [see 0010]. The “solutions that are sterilized” is interpreted as a pharmaceutically acceptable carrier and the term ”comprising” is an open language and so, the composition can have additional components in it. Dimarchi further teaches phosphate buffered saline solution with EDTA [0019 and 0082], which is nothing but modified peptide is soluble in the pharmaceutical acceptable carrier. The difference is that Dimarchi is silent on phosphorylated peptide. However, advantages of protein phosphorylation and its advantages are well established in the art. For example, see the following teachings of Topp: Top teaches a modified glucagon, wherein a glucagon molecule includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH, wherein the amino acid sequence of glucagon is HSQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ ID NO. 1), wherein glucagon is phosphorylated at Thr5 or Ser8 [see Table 3]. Topp further teaches that addition of a phosphate group on these residues can insert a charged and highly hydrophilic group into the core of a highly hydrophobic steric zipper, thus “opening” the zipper and inhibiting fibril formation. Moreover, the charged phosphate groups are expected to increase the solubility of the peptide, particularly at substantially neutral pH when the phosphate groups are in their fully ionized form. In the preferred embodiments, the computational models suggest that phosphorylation on, for example, Thr5 or Ser8 is very effective because those sites place the charge in the middle of the steric zipper, while, for example, phosphorylation at Ser2 may be less effective because the Ser2 side chain is not embedded in the zipper core. [See 0038-0041]. Therefore, one would be motivated to combine the teachings of Topp into the teachings of Dimarchi and arrive applicants claimed invention with a reasonable expectation of success. For claim 7: Dimarchi teach EDTA in the pharmaceutical compositions [see examples], wherein EDTA is an antioxidant. Topp also teaches that oxidation of Met27 and can be controlled with the addition of ethylene diamine tetraacetic acid (EDTA) and other formulation approaches known in the art [see 0021]. Topp further teaches that addition of antioxidants may prevent phosphoglucagon oxidation and improve the long-term storage stability of these peptides in solution [see 0080]. For claim 8: Though Dimarchi silent on phosphorylation, as explained above, Topp teaches that one or more phosphorylated amino acids in an analog of glucagon [see Table 2]. Topp further explained that it is also observed that four residues (Ser2, Thr5, Ser8 and Tyr10) that are involved in the most frequent contacts can be phosphorylated [See 0038-0041]. For claim 9-10: Though Dimarchi silent on phosphorylation, but Topp teaches that their composition is a prodrug of glucagon, wherein the functional group may be chemically or enzymatically cleaved. [see 0011 and 0039]. For claim 11: As explained above, Dimarchi teach EDTA in the pharmaceutical compositions [see examples], wherein EDTA is an antioxidant. Topp teaches that oxidation of Met27 and can be controlled with the addition of ethylene diamine tetraacetic acid (EDTA) and other formulation approaches known in the art [see 0021]. For claim 12: Dimarchi teaches phosphate buffered saline solution with EDTA [0019 and 0082]. Generally, differences in concentrations of components of a formulation will not support the patentability of subject matter encompassed by the prior art. Such formulations are results-effective variables which can be optimized. In in re Boesch, 617 F.2d 272,276, 205 USPQ 215, 219 (CCPA 1980), it was held that "discovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art." Further, in In re Aller, 220 F. 2d454, 456, 105 USPQ 233,235 (CCPA 1955) the courts maintained that: "Where the general condition of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." As formulating optimal compositions for medicaments is routine in the art of pharmacology, the claims are considered to be prima facie obvious. For claim 13: Dimarchi teaches that their composition comprising glucagon peptide and pharmaceutically acceptable carrier wherein the pH of the composition is at a physiologically acceptable pH [see 58]. The physiologically acceptable pH is interpreted as neutral pH. For claim 14: Dimarchi teaches various concentrations of their modified peptide, which ranges from 5-10 mg/ml [0082], or 15.1 mg to 24.7 mg [see examples]. Based on the above established facts from the cited prior art, it appears that all the claimed elements, i.e, applicants individual components in the composition and their advantages, were known in the prior art, and one skilled person in the art could have combined the elements as claimed by known relationships, with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art. The motivation to combine the art arise from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. See MPEP 2144.07. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited reference and to make the instantly claimed pharmaceutical composition with a reasonable expectation of success. The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Sernaker, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983). (ii) Claims 6-14 are rejected under 35 U.S.C. 103 as being unpatentable over Topp (US 2018/0298076 A1) in view of Dimarchi (US 2012/0196804 A1). For claim 6: Topp teaches a modified glucagon, wherein a glucagon molecule includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH, wherein the amino acid sequence of glucagon is HSQGTFTSDYSKYLDSRRAQDFVQWLMNT (SEQ ID NO. 1), wherein glucagon is phosphorylated at Thr5 or Ser8 [see Table 3]. Topp further exemplified their modified glucagon a sample containing glucagon, phospho-Ser2-, phospho-Thr5- or phospho-Ser8-glucagon at 1.6 mg/mL in 3.2 mM HCl, 0.9% NaCl (w/v) (pH 2.5) were added to 1× phosphate buffer saline (PBS), pH 7.4. [see Example 1]. The above is interpreted as pharmaceutical composition or formulation [see cf. 0057]. Topp define their formulation as the formulation maintains the chemical and physical stability of the active pharmaceutical ingredient (e.g., phosphoglucagon) to within acceptable limits after an extended period of storage at the intended storage conditions of the product. In some embodiments, a stable formulation has less than 10% degradation over two years or less than 5% degradation over two years. [see 0034]. Topp further exemplified solutions of phosphoglucagons and their chemically stability when stored for ten days at 5°C, 23°C and 37°C, wherein phosphoglucagon samples were prepared in 50 mM sodium phosphate, pH 7.4 and stored at 5°C., 23°C. and 37°C, did not show any chemical degradation after 10 days of storage of phospho-Thr5-glucagon (FIG. 6A) and phospho-Ser8-glucagon (FIG. 6B). Enhanced mass spectra of intact phosphoglucagon (m/z=891.1609, z=+4) at time t=0 compared with samples stored at 5°C, 23°C and 37°C showed no chemical degradation after 10 days of storage. However, low levels of singly and doubly oxidized degradation products were observed for both phospho-Thr5- and phospho-Ser8-glucagon samples stored at 37°C for 15 days (FIGS. 7A and 7B). The figures show the enhanced mass spectra of intact phosphoglucagon (m/z=891.1609, z=+4) at time t=0 compared with samples stored for 15 days. Tandem mass spectrometric (MS/MS) analysis confirms that the site of oxidation is residue Met 27 for both phospho-Thr5-glucagon and phospho-Ser8-glucagon. Addition of antioxidants may prevent phosphoglucagon oxidation and improve the long-term storage stability of these peptides in solution. In the above, no chemical degradation after 10 days of storage is interpreted as ‘less than 10% oxidation after 3 months when pharmaceutical composition is store at 30oC’. Differences between Topp and instant claim(s) are as follows: (i) Topp is silent on modified SEQ ID NO:1, wherein amino acid at position 27 is substituted with norleucine. (ii) Topp is silent on that modified peptide exhibits less than 10% oxidation after 3 months when the pharmaceutical composition is stored at 30oC. With regard to (i) and (ii) of above, Dimarchi cures these deficiencies, see below. Dimarchi teaches the following sequence: PNG media_image1.png 81 495 media_image1.png Greyscale [see SEQ ID NO:1]. The above sequence is identical to applicants SEQ ID NO:1. Dimarchi further teaches that the Met residue present at position 27 of the native peptide is changed to Leu or Nle (norleucine) to prevent oxidative degradation of the peptide, and these modified sequences having improved solubility and stability, these are represented by the following disclosed sequences in the teachings of Dimarchi: PNG media_image2.png 198 402 media_image2.png Greyscale [see abstract and page 4]. The above reads applicants claimed modified SEQ ID NO:1. The preventive oxidative degradation of the peptide is interpreted as or reads applicants ‘peptide exhibits less than 10% oxidation after 3 months when the pharmaceutical composition is stored at 30oC”. Therefore, a skilled person in the art would be motivated to replace Met 27 with norleucine, to avoid external addition of antioxidant and also replacement increases solubility and stability, as evidenced from the teachings of Dimarchi. For claim 7: Topp teachs that the oxidation of Met27 and can be controlled with the addition of ethylene diamine tetraacetic acid (EDTA) [see 0021]. Topp further teaches that addition of antioxidants may prevent phosphoglucagon oxidation and improve the long-term storage stability of these peptides in solution [see 0080]. For claim 8: Topp teaches that one or more phosphorylated amino acids in an analog of glucagon [see Table 2]. Topp further explained that it is also observed that four residues (Ser2, Thr5, Ser8 and Tyr10) that are involved in the most frequent contacts can be phosphorylated [See 0038-0041]. For claim 9-10: Topp teaches that their composition is a prodrug of glucagon, wherein the functional group may be chemically or enzymatically cleaved [see 0011 and 0039]. For claim 11: See For claim 7 above. For claim 12: Topp teaches PBS and EDTA in their compositions [see Example 1 and 0021]. For claim 13: Topp teaches pH 7.4, which is along the lines of applicants definition of substantially neutral pH, which is “A substantially neutral pH includes a physiological neutral pH of about 7.4”. For claim 14: Topp teaches concentration of phospho-Ser2-, phospho-Thr5- or phospho-Ser8-glucagon at 1.6 mg/mL [see Example 1]. Based on the above established facts from the cited prior art, it appears that all the claimed elements, i.e, applicants individual components in the composition and their advantages, were known in the prior art, and one skilled person in the art could have combined the elements as claimed by known relationships, with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art. The motivation to combine the art arise from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. See MPEP 2144.07. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited reference and to make the instantly claimed pharmaceutical composition with a reasonable expectation of success. The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Sernaker, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983). Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUDHAKAR KATAKAM whose telephone number is (571)272-9929. The examiner can normally be reached 8:30 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUDHAKAR KATAKAM/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Show 1 earlier event
Jan 06, 2025
Non-Final Rejection mailed — §103
Apr 30, 2025
Response Filed
Aug 01, 2025
Final Rejection mailed — §103
Feb 02, 2026
Request for Continued Examination
Feb 03, 2026
Response after Non-Final Action
Feb 09, 2026
Non-Final Rejection mailed — §103
Jul 10, 2026
Response Filed
Sep 29, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780875
POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12780876
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 1m to grant Granted Nov 03, 2026
Patent 12766196
PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS
3y 6m to grant Granted Oct 20, 2026
Patent 12760066
BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS
5y 0m to grant Granted Oct 13, 2026
Patent 12760070
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
75%
Grant Probability
98%
With Interview (+23.3%)
2y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1307 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month